BCRX

7.86

0.38% 0.03

Dopo l'orario di chiusura: 7.86

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Precedente Chiudi:

$7.83

Aprire:

$7.82

Volume 24 ore:

1.79M

Relative Volume:

0.60

Capitalizzazione di mercato:

$1.64B

Reddito:

$331.41M

Utile/perdita netta:

$-226.54M

Rapporto P/E:

-6.661

EPS:

-1.18

Flusso di cassa netto:

$-97.31M

1 W Prestazione:

-1.50%

1M Prestazione:

-7.20%

6M Prestazione:

+3.15%

1 anno Prestazione:

+54.72%

Intervallo 1D:

$7.69

$7.93

Intervallo di 1 settimana:

$7.69

$8.12

Portata 52W:

$4.03

$9.50

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Nome

Biocryst Pharmaceuticals Inc

Settore

Healthcare (1166)

Industria

Drug Manufacturers - Specialty & Generic (1)

Telefono

919-859-1302

Indirizzo

4505 EMPEROR BOULEVARD, DURHAM, NC

Dipendente

580

Cinguettio

@biocrystpharma

Prossima data di guadagno

2025-02-24

Ultimi documenti SEC

BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCRX Biocryst Pharmaceuticals Inc	7.86	1.64B	331.41M	-226.54M	-97.31M	-1.18
ZTS Zoetis Inc	163.11	73.07B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.05	47.43B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.24	45.72B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.08	17.28B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.81	14.03B	612.78M	-86.37M	-62.91M	-0.87

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-25	Iniziato	Wedbush	Outperform
2023-11-20	Ripresa	JP Morgan	Overweight
2023-09-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Aggiornamento	Jefferies	Hold → Buy
2023-07-13	Aggiornamento	BofA Securities	Neutral → Buy
2023-02-22	Aggiornamento	Needham	Hold → Buy
2022-11-02	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-05	Downgrade	Evercore ISI	Outperform → In-line
2022-08-05	Downgrade	Oppenheimer	Outperform → Perform
2022-04-18	Downgrade	Barclays	Overweight → Equal Weight
2022-04-11	Downgrade	BofA Securities	Buy → Neutral
2021-12-10	Iniziato	Oppenheimer	Outperform
2021-08-06	Downgrade	Jefferies	Buy → Hold
2021-08-03	Iniziato	Cantor Fitzgerald	Overweight
2021-03-01	Iniziato	Cowen	Outperform
2020-09-29	Ripresa	JP Morgan	Overweight
2020-06-17	Iniziato	BTIG Research	Neutral
2020-05-05	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-15	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Ripresa	Piper Jaffray	Overweight
2018-08-08	Ripresa	JP Morgan	Overweight
2018-07-17	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-06-22	Iniziato	Seaport Global Securities	Neutral
2018-01-02	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Iniziato	Barclays	Equal Weight
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-09-06	Aggiornamento	JP Morgan	Neutral → Overweight
2017-09-06	Aggiornamento	Jefferies	Hold → Buy
2017-02-16	Iniziato	Ladenburg Thalmann	Buy
2016-08-12	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-08-04	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	FBR Capital	Outperform
2016-02-09	Downgrade	JP Morgan	Overweight → Neutral
2016-02-09	Downgrade	Needham	Buy → Hold

Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

Mar 27, 2025

BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews

Mar 27, 2025

Mar 19, 2025

North Carolina biotech sues to block copies of $400M drug - The Business Journals

Mar 19, 2025

Mar 18, 2025

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance

Mar 18, 2025

Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego

Mar 18, 2025

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St

Mar 18, 2025

Mar 14, 2025

(BCRX) Technical Data - Stock Traders Daily

Mar 14, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 14, 2025

Mar 13, 2025

25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World

Mar 13, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com

Mar 12, 2025

Mar 11, 2025

BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Mar 11, 2025

BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada

Mar 11, 2025

BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law

Mar 11, 2025

BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView

Mar 11, 2025

BioCryst sues to protect ORLADEYO patents - Investing.com India

Mar 11, 2025

Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com

Mar 11, 2025

Mar 09, 2025

Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com

Mar 09, 2025

Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Mar 09, 2025

Mar 06, 2025

Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News Today

Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com

Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK

Mar 06, 2025